Morgan Stanley Eyes Emerging Growth for Grail (GRAL) as Sector Valuations Reach Equilibrium

3 days ago 7

Maham Fatima

Sun, December 28, 2025 astatine 9:05 AM CST 2 min read

Grail Inc. (NASDAQ:GRAL) is 1 of the best emerging exertion stocks to put in. On December 1, Morgan Stanley assumed sum of Grail with an Equal Weight standing and a terms people of $110, which was up from $85. Heading into 2026, the steadfast is optimistic astir the Life Science space, noting respective emerging maturation drivers. While the steadfast likes the industry’s semipermanent setup, it argued that a caller valuation spike has near banal prices astatine a tenable equilibrium.

In Q3 2025, Grail highlighted a 26% year-over-year gross summation to $36.2 million. This maturation was driven by the Galleri multi-cancer aboriginal detection test, which saw screening gross emergence 29% to $32.8 million. The institution sold implicit 45,000 Galleri tests during the quarter, representing a 39% summation successful measurement compared to the anterior year. Efficiency gains from its high-throughput level besides helped amended non-GAAP adjusted gross margins to 55%, a important leap from 41% successful Q3 2024. Despite the gross growth, Grail reported a nett nonaccomplishment of $89 cardinal for the quarter, though this was a 29% betterment implicit the erstwhile year.

Morgan Stanley Eyes Emerging Growth for Grail (GRAL) arsenic Sector Valuations Reach Equilibrium

Clinical milestones during the 4th included affirmative information from the PATHFINDER 2 and SYMPLIFY studies. Results showed that adding Galleri to modular screenings led to a sevenfold summation successful crab detection rates with a precocious specificity of 99.6%. Furthermore, semipermanent follow-up from the SYMPLIFY survey accrued the test’s affirmative predictive worth to 84.2%, arsenic galore archetypal mendacious positives were aboriginal diagnosed with crab astatine the tract predicted by Galleri. The institution besides announced a caller concern with Samsung to commercialize the trial successful South Korea, Japan, and Singapore.

Grail Inc. (NASDAQ:GRAL) is simply a commercial-stage healthcare institution that provides multi-cancer aboriginal detection investigating and services successful the US and internationally.

While we admit the imaginable of GRAL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.